Solu-Medrol (Methylprednisolone Sodium Succinate) – Anti-inflammatory | HongKong DengYue Medicine

MPSS Application Scope

Solu-Medrol is indicated for the treatment of various inflammatory and autoimmune conditions, including:

• Severe allergic reactions

• Asthma and chronic obstructive pulmonary disease (COPD) exacerbations

• Autoimmune disorders such as systemic lupus erythematosus and rheumatoid arthritis

• Acute inflammatory conditions like cerebral edema and severe skin diseases

• Immunosuppressive therapy in organ transplantation

  

MPSS Characteristics

• Ingredients: Methylprednisolone Sodium Succinate

• Properties:​ A white or nearly white, odorless, hygroscopic, amorphous solid

• Packaging Specification:​ Available in various strengths: 40 mg, 125 mg, 500 mg, 1 g, and 2 g per vial

• Storage:​ Store reconstituted solution at room temperature (15–30°C)

• Expiry Date: Refer to the expiration date printed on the packaging

• Executive Standard: Complies with the United States Pharmacopeia (USP) standards for injectable corticosteroids

• Approval Number: FDA Application Number: NDA 011856

• Date of Revision: Latest revision as of June 5, 2024

• Manufacturer: Pfizer Inc.

Guidelines for the Use of  MPSS

• Dosage and Administration:

  • Recommended Dose:

    • Dosage varies based on the specific condition being treated, the severity of the condition, and the patient’s response to therapy.

    • Typical dosing ranges from 40 mg to 1 g per day, administered intravenously or intramuscularly.

  • Administration:

    • Reconstitute the powder with the provided diluent or an appropriate sterile diluent.

    • Administer via slow intravenous injection, intravenous infusion, or intramuscular injection, depending on clinical circumstances.

  • Missed Dose:​

    • If a dose is missed, administer as soon as possible unless it is near the time for the next dose.

    • Do not administer two doses at the same time to make up for a missed dose

• Adverse Reactions:

  • Common Adverse Reactions:

    • Fluid retention

    • Elevated blood pressure

    • Hyperglycemia

    • Mood swings

    • Insomnia

  • Serious Adverse Reactions:

    • Increased risk of infections

    • Osteoporosis with long-term use

    • Gastrointestinal bleeding

    • Psychiatric disturbances

    • Cushingoid appearance

    • Adrenal suppression

    ​

• Contraindications:

  • Systemic fungal infections

  • Known hypersensitivity to methylprednisolone sodium succinate or any component of the formulation

  • Administration of live or live attenuated vaccines during therapy

• Precautions:

  • Use with caution in patients with a history of tuberculosis, peptic ulcer disease, or psychiatric disorders.

  • Gradual withdrawal is recommended after prolonged therapy to prevent adrenal insufficiency.

  • Monitor blood glucose levels in diabetic patients.

  • Avoid abrupt discontinuation to prevent withdrawal symptoms.

MPSS Interactions

• May interact with nonsteroidal anti-inflammatory drugs (NSAIDs), increasing the risk of gastrointestinal bleeding.

• Concurrent use with diuretics may enhance the risk of hypokalemia.

• Anticholinesterase agents may have reduced efficacy.

• Live vaccines may have reduced efficacy and increased risk of adverse reactions.

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.